Pfizer sells Sandwich site
Pfizer has finally found a buyer for its Sandwich site in Kent, having completed the sale to a private consortium. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/pfizer_sells_sandwich_site_976851
Search results
Found 5,198 pages
AUTHOR: Kevin Grogan
Skyepharma's Flutiform in COPD trials
The UK’s Skyepharma says that partner Mundipharma has commenced an international clinical trial of the firms’ asthma drug Flutiform for the treatment of chronic obstructive pulmonary disease. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/skyepharmas_flutiform_in_copd_trials_1005720FDA employees return to work
FDA employees return to work - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/fda_employees_return_to_work_1005871Europe approval for GSK/Theravance COPD drug
GlaxoSmithKline and partner Theravance are celebrating after the European Commission granted marketing authorisation for their chronic obstructive pulmonary disease Anoro. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/europe_approval_for_gsktheravance_copd_drug_1001914Genmab multiple myeloma drug shines in Phase II
Genmab and partner Johnson & Johnson have been boosted by positive mid-stage data on daratumumab for multiple myeloma. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/genmab_multiple_myeloma_drug_shines_in_phase_ii_970988Icon seals acquisition of Aptiv
Ireland-based clinical research organisation giant Icon has completed its $143.5 million acquisition of Aptiv Solutions. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/icon_seals_acquisition_of_aptiv_1001917Europe approves Baxter/Halozyme's HyQvia
The European Commission has given the green light to Baxter International and Halozyme Therapeutics' HyQvia as replacement therapy for adults with primary and secondary immunodeficiencies. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/europe_approves_baxterhalozymes_hyqvia_1005059UCB acquires Lectus assets
UCB has acquired the key pharmaceutical assets of the UK's Lectus Therapeutics, boosting its efforts in the central nervous system field. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/ucb_acquires_lectus_assets_980012Pharmacyclics up for sale: Bloomberg
It has been reported by Bloomberg that Pharmacyclics, which discovered the cancer drug Imbruvica, is looking for buyers and partner Johnson & Johnson and Novartis are cited as possible acquirers. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/pharmacyclics_up_for_sale_bloomberg_971114Acacia raises £15 million
The UK's Acacia Pharma has raised £15 million to finance late-stage development of its treatments designed to prevent nausea and vomiting in cancer patients. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/acacia_raises_15_million_1005626
